Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	46.04	309.1
Short-Term Investments	169.94	-
Cash & Cash Equivalents	215.98	309.1
Cash Growth	-30.13%	-
Other Current Assets	7.25	1.05
Total Current Assets	223.23	310.15
Property, Plant & Equipment	0.41	0.24
Long-Term Investments	17.67	-
Goodwill and Intangibles	4.81	4.93
Other Long-Term Assets	2.88	0.45
Total Long-Term Assets	25.78	5.63
Total Assets	249.01	315.78
Accounts Payable	2.01	5.08
Current Debt	1.64	0.86
Other Current Liabilities	9.13	5.21
Total Current Liabilities	12.78	11.15
Long-Term Debt	3.44	4.15
Total Long-Term Liabilities	3.44	4.15
Total Liabilities	16.23	15.3
Total Debt	5.08	5.01
Debt Growth	1.50%	-
Retained Earnings	-114.11	-39.23
Comprehensive Income	0.3	-
Shareholders' Equity	-92.55	-24.85
Net Cash (Debt)	210.9	304.09
Net Cash (Debt) Growth	-30.65%	-
Working Capital	210.45	299

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).